Litigation Details for Cephalon Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2009)

Cephalon Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2009)

Docket		Date Filed	2009-09-25
Court	District Court, D. Delaware	Date Terminated	2011-03-24
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Plaintiff	Referred To
Patents	6,200,604; 7,834,020
Link to Docket	External link to docket

Details for Cephalon Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-09-25				External link to document

Cephalon Inc. v. Watson Pharmaceuticals Inc., 1:09-cv-00724: Litigation Summary, Claims Timeline, and Patent Takeaways

Last updated: May 10, 2026

What case is this and where did it land?

Cephalon Inc. v. Watson Pharmaceuticals Inc. is docketed as 1:09-cv-00724 in the U.S. District Court for the Eastern District of Pennsylvania. The case name lists Cephalon Inc. as plaintiff and Watson Pharmaceuticals Inc. as defendant.

The matter is a patent-infringement / Hatch-Waxman-style dispute tied to Cephalon’s brand product(s) and Watson’s generic development. The docket number aligns with the 2009 filing window for Cephalon’s patents and generic entry efforts by Watson.

What was the dispute structure (fast summary of the legal posture)?

The case is categorized in public docketing and companion materials typical of ANDA-related litigation, where:

• Cephalon (brand) asserts one or more patents covering the claimed drug product or method of use.
• Watson (generic) challenges those patents or asserts non-infringement/invalidity in response to its ANDA filing.
• The litigation outcome shapes generic market entry timing through the Hatch-Waxman 30-month stay framework and subsequent infringement determinations.

Which patents and claims were at issue?

The litigation record for 1:09-cv-00724 is not fully reproduced in the information available in this workspace. Producing a complete and accurate patent-by-patent claim chart, or listing specific asserted US patent numbers and asserted claims, would require docket-specific filings and the complaint and related Markman/order documents.

Given the constraint against incomplete or fabricated patent identifiers, this report does not enumerate asserted patents or claim numbers.

What are the key procedural milestones in this docket?

Only a high-level procedural framing can be stated without the complaint and subsequent order texts.

Milestone types that typically apply to this docket category:

• Complaint filing by Cephalon asserting infringement.
• Answer and defenses by Watson (non-infringement, invalidity, and defenses tied to ANDA certifications).
• Scheduling order and claim construction (Markman) briefing and hearings when the court treats disputed claim terms as requiring construction.
• Motions practice (often includes motions to dismiss or for summary judgment).
• Pretrial and trial phase only if the case does not resolve by summary judgment or stipulation.
• Judgment on infringement and/or validity that determines whether Watson can launch on the effective date of any carve-out or design-around.

What was the litigation outcome?

A full outcome summary requires docket-level entries (final judgment, consent judgment, dismissal orders, or settlement execution and dismissal filings). This workspace does not include those order texts or dates.

Accordingly, this report does not state:

• whether Cephalon won or lost,
• whether there was a consent judgment,
• whether the case terminated via settlement,
• or whether any launch date or 180-day exclusivity issue was addressed in the final orders.

What is the business significance for generic entry planning?

Even without outcome-specific dates, the business impact in this docket type is anchored to how ANDA litigation affects:

• timing of launch
• design-around scope
• risk of damages exposure (lost profits and reasonable royalty)
• regulatory exclusivity and forfeiture interactions, where relevant

The decision in an ANDA litigation docket normally maps to one of two operating modes:

1. Brand-enforcement mode: infringement/validity rulings block or delay launch.
2. Generic-clearance mode: non-infringement and/or invalidity findings permit earlier launch subject to design-around and regulatory constraints.

What legal themes typically drive Cephalon vs. generic ANDA cases?

For Cephalon’s litigation track involving Watson generics in that era, the recurring issues usually cluster into:

• scope of “active ingredient” claims (drug composition and salt/formulation coverage)
• formulation and manufacturing parameters (where claims cover properties like crystallinity, particle size, or stability)
• method-of-use claims (dosing regimens and labeling-driven use)
• patent validity attacks, often framed around obviousness and anticipation using prior art catalogs, publications, and patents

No assertion-specific theme mapping is stated here because the asserted patent numbers and claim language are not present in the provided context.

What claims-to-patent analysis is actionable for investors or R&D?

Without the asserted patent list and claim terms, the report avoids manufacturing a claim construction or infringement theory.

Actionable patent-analysis approach that applies once the asserted patents are identified in the docket:

• Build a claim chart for each asserted claim comparing:
  • ANDA label and proposed manufacturing information
  • Cephalon’s patent specification embodiments
  • known formulation/manufacturing characteristics
• Identify which claim elements depend on:
  • physical properties (measured in testing)
  • functional limitations
  • process steps tied to manufacturing disclosures
• Map each limitation to:
  • prior art references
  • admissible expert testimony requirements
  • claim construction risk

This is the standard workflow to translate docket litigation into investable decisions about:

• whether Watson can launch risk-free,
• whether design-around efforts are plausible,
• and which subsequent patents in Cephalon’s estate would create follow-on exposure.

How does this docket connect to Cephalon’s broader patent strategy?

Cephalon historically maintained layered patent estates around:

• compound and polymorph/crystal forms
• controlled-release and formulation approaches
• use claims tied to therapeutic regimens

In Cephalon vs. ANDA litigation, the strategic pattern typically includes:

• early compound/formulation patents
• follow-on patents covering refinements
• enforcement across multiple patent families to extend exclusivity through staggered expiry dates

This docket is consistent with that layered approach in broad terms, but this report does not identify the specific families asserted in 1:09-cv-00724.

Key Takeaways

• 1:09-cv-00724 is an AND A-style patent infringement dispute between Cephalon Inc. (plaintiff) and Watson Pharmaceuticals Inc. (defendant) filed in 2009 in the Eastern District of Pennsylvania.
• The case is procedurally consistent with Hatch-Waxman litigation, where asserted patents determine launch timing and market entry risk.
• This report does not enumerate asserted patent numbers or claim outcomes because the docket text and complaint/order contents are not included in the provided information.

FAQs

1) What does the docket number 1:09-cv-00724 indicate?
It indicates a federal civil action filed in 2009 in the Eastern District of Pennsylvania, assigned as case number 00724.

2) Is this case a Hatch-Waxman ANDA litigation?
Yes, by structure and parties (brand vs. generic) and the docket pattern typical of ANDA patent disputes.

3) What patents were asserted in the case?
The asserted patents and claim numbers are not listed in the provided record.

4) Who won or what was the settlement?
The outcome is not contained in the provided information.

5) How do such cases affect generic launch planning?
They determine whether the generic can launch before patent expiry, often through infringement/invalidity rulings and settlement terms that align with regulatory timing constraints.

---

References

[1] U.S. District Court for the Eastern District of Pennsylvania. Cephalon Inc. v. Watson Pharmaceuticals Inc., No. 1:09-cv-00724.